Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sample size re-estimation: recent developments and practical considerations.

A L Gould1

  • 1Merck Research Laboratories, West Point, PA 19486, U.S.A. goulda@merck.com

Statistics in Medicine
|August 28, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Strain-level diversity of symbiont communities between individuals and populations of a bioluminescent fish.

The ISME journal·2023
Same author

Chromosome-Level Genome Assembly of the Bioluminescent Cardinalfish Siphamia tubifer: An Emerging Model for Symbiosis Research.

Genome biology and evolution·2022
Same author

Life history of the symbiotically luminous cardinalfish Siphamia tubifer (Perciformes: Apogonidae).

Journal of fish biology·2016
Same author

Segregation effects on the properties of (AuAg)₁₄₇.

Physical chemistry chemical physics : PCCP·2014
Same author

Symbiosis initiation in the bacterially luminous sea urchin cardinalfish Siphamia versicolor.

Journal of fish biology·2012
Same author

Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.

Diabetes, obesity & metabolism·2009
Same journal

A Causal Framework for Evaluating the Total Effect of Strategies Aiming to Expand Screening and to Improve Outcomes.

Statistics in medicine·2026
Same journal

Causal Effects on Nonterminal Event Time With Application to Antibiotic Usage and Future Resistance.

Statistics in medicine·2026
Same journal

Subgroup Analysis of Interval-censored Failure Time Data With Application to Alzheimer's Disease.

Statistics in medicine·2026
Same journal

Rejoinder to Commentaries on "A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events".

Statistics in medicine·2026
Same journal

A Multi-Stage Drop-the-Loser Design With Superiority Boundaries.

Statistics in medicine·2026
Same journal

Interpretable ROI Identification in Brain Image Analysis: Overcoming CNN Black Box Challenges With Kriging-Enhanced Adaptive Sampling.

Statistics in medicine·2026
See all related articles

Clinical trial interim analyses can adjust sample size for statistical power. Strategic considerations, like avoiding data unblinding and managing enrollment risks, are crucial for effective sample size re-estimation.

Area of Science:

  • Clinical trial methodology
  • Biostatistics
  • Regulatory science

Background:

  • Interim analyses in clinical trials can enhance statistical power by adjusting sample size.
  • Various strategies exist, including internal pilot studies, blinded sample size adjustment, and conditional power calculations.

Purpose of the Study:

  • To explore the strategic considerations and implications of interim analyses for clinical trial sample size adjustments.
  • To evaluate the suitability of different interim analysis methods based on regulatory preferences and trial design.

Main Methods:

  • Review of existing strategies for interim examinations and sample size re-estimation.
  • Discussion of simulation study findings regarding type I error control and power.
  • Analysis of strategic issues including data unblinding, enrollment risks, and trial duration.

Related Experiment Videos

Main Results:

  • Alternative interim analysis methods generally control Type I error rates adequately, but power can be variable.
  • Strategic factors, rather than numerical aspects, are paramount in sample size re-estimation.
  • Regulatory bodies favor methods that avoid unblinding data before trial completion.

Conclusions:

  • Sample size re-estimation and interim efficacy analyses can be integrated into trial designs.
  • Careful consideration of enrollment dynamics and follow-up duration is necessary.
  • For trials with long follow-up relative to recruitment, conservative initial sample size estimation with interim efficacy evaluation may be preferable.